IQVIA Holdings Inc. $IQV Stock Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,186 shares of the medical research company’s stock after selling 4,755 shares during the period. IQVIA comprises 2.2% of Washington Trust Advisors Inc.’s holdings, making the stock its 13th biggest holding. Washington Trust Advisors Inc.’s holdings in IQVIA were worth $31,237,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in IQVIA during the second quarter valued at approximately $2,811,292,000. Canada Pension Plan Investment Board acquired a new position in IQVIA in the second quarter worth approximately $240,911,000. Bank of America Corp DE acquired a new position in IQVIA in the second quarter worth approximately $235,551,000. Legal & General Group Plc bought a new position in shares of IQVIA in the second quarter valued at $211,342,000. Finally, Bank of New York Mellon Corp bought a new position in shares of IQVIA in the second quarter valued at $180,296,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IQV. TD Cowen increased their price objective on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. UBS Group began coverage on IQVIA in a report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 target price on the stock. Jefferies Financial Group boosted their target price on IQVIA from $220.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Mizuho upped their target price on IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. Finally, Evercore increased their price target on IQVIA from $275.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $278.75.

Insider Buying and Selling at IQVIA

In other news, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock valued at $3,796,021 in the last ninety days. Company insiders own 1.70% of the company’s stock.

IQVIA Trading Up 0.4%

Shares of NYSE:IQV traded up $1.15 during mid-day trading on Friday, hitting $279.47. The stock had a trading volume of 981,209 shares, compared to its average volume of 1,322,001. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market cap of $46.00 billion, a PE ratio of 34.67, a P/E/G ratio of 2.45 and a beta of 1.17. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $282.98. The company’s 50 day moving average is $263.98 and its 200-day moving average is $216.43.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.54 EPS for the current year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.